GammaDelta Therapeutics: New at the top
London-based immunotherapy developer GammaDelta Therapeutics has hired Paolo Paoletti as Chief Executive Officer. Paoletti was formerly the first appointed President of GSK Oncology, where he was responsible for the overall oncology business.
Most recently, Paoletti was Chief Executive Officer of Kesios Therapeutics Ltd. Prior to join GSK, he was Vice President of Oncology Clinical Research at Lilly.
Paoletti has a degree in Medicine from the University of Pisa in Italy, where he was professor in Pulmonary Diseases and authored more than 300 publications. He is currently a non-executive director for Genmab, PsiOxus Therapeutics (Chairman of the Board), FORMA Therapeutics and Nucana Biomed.
GammaDelta Therapeutics also appointed Natalie Mount as Chief Scientific Officer.
Adobe stock photos - https://european-biotechnology.com/latest-news/roche-moves-obesity-asset-ct-388-into-phase-iii/
X-act Cologne Clinical Research GmbH
NATO